Tryp Therapeutics Inc (OTCMKTS:TRYPF) Stock Makes An Interesting After The Recent Development
Tryp Therapeutics Inc (OTCMKTS:TRYPF) stock saw selling pressure on Tuesday as investors preferred to book profit at higher level. The stock is still up 23% over the past week.
Market Action
In the previous trading session, TRYPF stock decreased 8.30% to $0.3632. A total of 93K shares traded for the session hands, above its average volume of 114K shares. The stock opened at $0.40 and moved in a range of $0.3337 – 0.4000.
Key Trigger
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Redefining Standards, Refining Psychiatry
Tryp Therapeutics announced its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.
The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new opportunity with drugs such as psilocybin, LSD, MDMA, DMT, and others to address hard-to-treat mental health diseases, namely depression, addiction, post-traumatic stress disorder and anxiety. As strides are being made on those fronts, a second investment wave is swelling on the horizon that looks to feature expanded indications and bring new therapeutic options to diseases with unmet needs.
Psychedelics could redefine standards of care for chronic diseases and reshape psychiatry, including counseling practices, among other things. Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is leading this next wave of psychedelic drug development beyond mental health into chronic pain and eating disorders as the company advances its clinical programs.
